-+ 0.00%
-+ 0.00%
-+ 0.00%

Incyte Wins EU Approval for Povofortay to Treat Hidradenitis Suppurativa

PUBT·11/16/2026 21:32:23
Listen to the news
Incyte Wins EU Approval for Povofortay to Treat Hidradenitis Suppurativa
  • European Commission approves Incyte’s Povofortay for eligible adults with moderate to severe hidradenitis suppurativa.
  • The treatment is the EU’s first once-daily oral option for this indication, available in 45 mg and 75 mg doses.
  • FDA review is ongoing, with U.S. approval and launch anticipated in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20261116905792) on November 16, 2026, and is solely responsible for the information contained therein.